Aims: Among the main disadvantages of currently available Δ9-tetrahydrocannabinol (THC) formulations are dosing difficulties due to poor pharmacokinetic characteristics. Namisol® is a novel THC formulation, designed to improve THC absorption. The study objectives were to investigate the optimal administration route, pharmacokinetics (PK), pharmacodynamics (PD) and tolerability of Namisol®. Methods: This first in human study consisted of two parts. Panel I included healthy males and females (n = 6/6) in a double-blind, double-dummy, randomized, crossover study with sublingual (crushed tablet) and oral administration of Namisol® (5mg THC). Based on these results, male and female (n = 4/5) participants from panel I received oral THC 6.5 and 8.0mg or matching placebo in a randomized, crossover, rising dose study during panel II. PD measurements were body sway; visual analogue scales (VAS) mood, psychedelic and heart rate. THC and 11-OH-THC population PK analysis was performed. Results: Sublingual administration showed a flat concentration profile compared with oral administration. Oral THC apparent t1/2 was 72-80min, tmax was 39-56min and Cmax 2.92-4.69ngml-1. THC affected body sway (60.8%, 95% CI 29.5, 99.8), external perception (0.078 log mm, 95% CI 0.019, 0.137), alertness (-2.7mm, 95% CI -4.5, -0.9) feeling high (0.256 log mm, 95% CI 0.093, 0.418) and heart rate (5.6 beatsmin-1, 95% CI 2.7, 6.5). Namisol® was well tolerated. CONCLUSIONS Oral Namisol® showed promising PK and PD characteristics. Variability and tmax of THC plasma concentrations were smaller for Namisol® than reported for studies using oral dronabinol and nabilone. This study was performed in a limited number of healthy volunteers. Therefore, future research on Namisol® should study clinical effects in patient populations. © 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.
CITATION STYLE
Klumpers, L. E., Beumer, T. L., van Hasselt, J. G. C., Lipplaa, A., Karger, L. B., Kleinloog, H. D., … van Gerven, J. M. A. (2012). Novel Δ9-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. British Journal of Clinical Pharmacology, 74(1), 42–53. https://doi.org/10.1111/j.1365-2125.2012.04164.x
Mendeley helps you to discover research relevant for your work.